Search alternatives:
significant treatment » significant investment (Expand Search), significant enrichment (Expand Search), significant impairment (Expand Search)
treatment decrease » treatment decreased (Expand Search), treatments decreased (Expand Search), treatment increases (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
Showing 1 - 20 results of 5,731 for search '(( significant treatment decrease ) OR ( significant ((gap decrease) OR (nn decrease)) ))', query time: 0.46s Refine Results
  1. 1
    Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments.

    Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

    Published 2025
    Save to List
    Saved in:
  2. 2
    AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation.

    AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

    Published 2025
    Save to List
    Saved in:
  3. 3
    Detailed treatment status of people who received non- pharmacological treatment at first diagnosis.

    Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Treatment at first diagnosis of insomnia disorder (%).

    Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later.

    Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 7
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 8
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 10
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 11
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 12
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  13. 13
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  14. 14
    Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019).

    Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Transepithelial resistance of NHBE decreases significantly after PAA exposure.

    Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

    Published 2025
    Save to List
    Saved in:
  16. 16
    Brain regions with significantly decreased activations for the Raven task are shown in blue.

    Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

    Published 2025
    Save to List
    Saved in:
  17. 17
    Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year.

    Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia disorder.

    Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    General information of patient who diagnosis insomnia disorder (N = 518,119).

    General information of patient who diagnosis insomnia disorder (N = 518,119). by Mingee Choi (15250732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Summary of significant treatment × time effect.

    Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

    Published 2024
    Save to List
    Saved in:

Search Tools: